CY 208-243

CY 208-243 is a selective dopamine D1 receptor agonist which exhibits antiparkinsonian activity[1].

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

dopamine D1 receptor[1]

Pretreatment with CY 208-243 (2.5 mg/kg; s.c.) prevents the increase of DA release and metabolism induced by the D-1 antagonist, SCH 23390 (0.05 mg/kg; s.c.)[1]. Animal Model: Male Sprague-Dawley rats (180-200 g)[1] Dosage: 2.5 mg/kg Administration: Subcutaneous Result: Prevented the increase of DA release and metabolism induced by the D-1 antagonist.

[1]. Imperato A, et al. CY 208-243, a novel dopamine D-1 receptor agonist, fails to modify dopamine release in freely moving rats. Eur J Pharmacol. 1989 Jan 24;160(1):155-8.

[2]. Temlett JA, et al. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206.